Ngā hua rapu - Ming‐Shyang Huang

  • E whakaatu ana i te 1 - 3 hua o te 3
Whakamahine hua
  1. 1
    Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

    Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells mā An-Fu Lee, Man‐Chin Chen, Chao‐Ju Chen, Chih‐Jen Yang, Ming‐Shyang Huang, Yu‐Peng Liu

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    <scp>PCAF</scp>‐mediated acetylation of <scp>ISX</scp> recruits <scp>BRD</scp>4 to promote epithelial‐mesenchymal transition

    <scp>PCAF</scp>‐mediated acetylation of <scp>ISX</scp> recruits <scp>BRD</scp>4 to promote epithelial‐mesenchymal transition mā Li‐Ting Wang, Kwei‐Yan Liu, W.Y. Jeng, Cheng‐Ming Chiang, Chee‐Yin Chai, Shyh‐Shin Chiou, Ming‐Shyang Huang, Kazunari K. Yokoyama, Shen‐Nien Wang, Shau‐Ku Huang, Shih‐Hsien Hsu

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

    Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients... mā Shih-Lung Cheng, Ming-Lin Ho, Yun-Fa Lai, Hao‐Chien Wang, Jeng‐Yuan Hsu, Shih‐Feng Liu, Ming-Shyang Huang, Cheng-Hung Lee, Ching‐Hsiung Lin, Liang‐Wen Hang, Yu‐Chih Liu, Kuang‐Yao Yang, Jia-Horng Wang

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Errata/Corrigenda
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: